A5042324481- Fibroblast Growth Factor Research
- Kruppel-like factors research
- Neuropeptides and Animal Physiology
- Pancreatic function and diabetes
- Receptor Mechanisms and Signaling
- Sleep and Wakefulness Research
- Neuroscience and Neuropharmacology Research
- Regulation of Appetite and Obesity
- Diabetes Treatment and Management
- Parathyroid Disorders and Treatments
University of Alabama at Birmingham
2020-2025
Glucagon regulates glucose and lipid metabolism promotes weight loss. Thus, therapeutics stimulating glucagon receptor (GCGR) signaling are promising for obesity treatment; however, the underlying mechanism(s) have yet to be fully elucidated. We previously identified that hepatic GCGR increases circulating fibroblast growth factor 21 (FGF21), a potent regulator of energy balance. reported mice deficient liver Fgf21 partially resistant GCGR-mediated loss, implicating FGF21 as glucagon's loss...
Abstract The reduction of neuropeptide Y (NPY), an abundant neuromodulator in the brain, has been implicated multiple neuropsychiatric disorders, such as depression and post-traumatic stress disorder (PTSD). CA1 region hippocampus is important area for anxiety highly expresses NPY. Injection NPY into anxiolytic shown to alleviate behavioral symptoms a model traumatic stress. It known that activation Y1 receptors effects NPY’s are blocked by receptor antagonist. However, location mediating...
In chronic kidney disease (CKD), elevated serum levels of fibroblast growth factor 23 (FGF23) and phosphate are associated with various pathologies, including systemic inflammation anemia. Experimental studies have shown that high can accelerate CKD‐associated but direct effects circulating on tissues not well described. Our objective was to compare the versus FGF23 primary murine hepatocytes determine their respective contributions anemia in context CKD. We postulate CKD, elevations...
Abstract Glucagon is an essential regulator of glucose and lipid metabolism. We have reported that chronic glucagon receptor (GCGR) activation with the highly selective, long-acting GCGR-agonist, IUB288, promotes weight-loss by stimulating energy expenditure suppressing food intake in diet-induced obese (DIO) mice. Thus, novel therapeutics include agonism emerged as promising candidates for obesity diabetes. GCGR-stimulated predominately dependent on hepatic GCGR activation; however,...